Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor–Positive Cells and Pathogenesis of Cholestatic Liver Disease

Gastroenterology

Volumn 154, Issue 8, 2018, Pages 2178-2193

  Tedesco, Dana ^a   Thapa, Manoj ^a   Chin, Chui Yoke ^a   Ge, Yong ^b   Gong, Minghao ^b   Li, Jing ^b   Gumber, Sanjeev ^a   Speck, Patrick ^a   Elrod, Elizabeth J ^a   Burd, Eileen M ^a,c   Kitchens, William H ^a   Magliocca, Joseph F ^a   Adams, Andrew B ^a   Weiss, David S ^a   Mohamadzadeh, Mansour ^b,d   Grakoui, Arash ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Florida   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Immune Response; Intestinal Microbiota; Liver Disease Pathogenesis; PSC

Indexed keywords

DNA 16S; INTERLEUKIN 17; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; ABC TRANSPORTER SUBFAMILY B; LYMPHOCYTE ANTIGEN RECEPTOR; P-GLYCOPROTEIN 2;

ARTICLE; BACKCROSSING; CD4+ T LYMPHOCYTE; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DNA SEQUENCE; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTESTINE FLORA; LACTOBACILLUS GASSERI; LIVER CELL; LIVER FIBROSIS; LIVER HOMOGENATE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BILE DUCT; BLOOD; CELL CULTURE; CHOLESTASIS; CYTOLOGY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; INTRAEPITHELIAL LYMPHOCYTE; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; SCLEROSING CHOLANGITIS; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; BILE DUCTS; CELLS, CULTURED; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DISEASE MODELS, ANIMAL; END STAGE LIVER DISEASE; FEMALE; GASTROINTESTINAL MICROBIOME; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-17; INTRAEPITHELIAL LYMPHOCYTES; LACTOBACILLUS GASSERI; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; YOUNG ADULT;

EID: 85047723725     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.02.019     Document Type: Article

References (49)

1. Davit-Spraul, A., Gonzales, E., Baussan, C., et al. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 30 (2010), 134–146.
2. Fickert, P., Fuchsbichler, A., Wagner, M., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127 (2004), 261–274.
3. Petruzzelli, M., Vacca, M., Moschetta, A., et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem 40 (2007), 503–510.
4. Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 (1993), 451–462.
5. Gupta, A., Bowlus, C.L., Primary sclerosing cholangitis: etiopathogenesis and clinical management. Front Biosci (Elite Ed) 4 (2012), 1683–1705.
6. Tabibian, J.H., Lindor, K.D., Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 7 (2013), 103–114.
7. Tabibian, J.H., Talwalkar, J.A., Lindor, K.D., Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int, 2013, 2013, 389537.
8. Karlsen, T.H., Schrumpf, E., Boberg, K.M., Update on primary sclerosing cholangitis. Dig Liver Dis 42 (2010), 390–400.
9. Bjoro, K., Brandsaeter, B., Foss, A., et al. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 26 (2006), 69–79.
10. Loftus, E.V. Jr., Harewood, G.C., Loftus, C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54 (2005), 91–96.
11. Gao, B., Jeong, W.I., Tian, Z., Liver: An organ with predominant innate immunity. Hepatology 47 (2008), 729–736.
12. Paget, C., Chow, M.T., Gherardin, N.A., et al. CD3bright signals on gammadelta T cells identify IL-17A-producing Vgamma6Vdelta1+ T cells. Immunol Cell Biol 93 (2015), 198–212.
13. Roark, C.E., Vollmer, M.K., Campbell, P.A., et al. Response of a gamma delta(+) t cell receptor invariant subset during bacterial infection. J Immunol 156 (1996), 2214–2220.
14. Martin, B., Hirota, K., Cua, D.J., et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31 (2009), 321–330.
15. Duan, J., Chung, H., Troy, E., et al. Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. Cell Host Microbe 7 (2010), 140–150.
16. Zhao, N., Hao, J., Ni, Y., et al. Vγ4 T cell-derived IL-17A negatively regulates NKT cell function in Con A-induced fulminant hepatitis. J Immunol 187 (2011), 5007–5014.
17. Rao, R., Graffeo, C.S., Gulati, R., et al. Interleukin 17-producing γδ T cells promote hepatic regeneration in mice. Gastroenterology 147 (2014), 473–484.e2.
18. Hammerich, L., Bangen, J.M., Govaere, O., et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59 (2014), 630–642.
19. Mehta, P., Nuotio-Antar, A.M., Smith, C.W., Gammadelta T cells promote inflammation and insulin resistance during high fat diet-induced obesity in mice. J Leukoc Biol 97 (2015), 121–134.
20. Klemann, C., Schröder, A., Dreier, A., et al. Interleukin 17, produced by γδ T cells, contributes to hepatic inflammation in a mouse model of biliary atresia and is increased in livers of patients. Gastroenterology 150 (2016), 229–241.e5.
21. Fabre, T., Kared, H., Friedman, S.L., et al. IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol 193 (2014), 3925–3933.
22. Ishak, K., Baptista, A., Bianchi, L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995), 696–699.
23. Velazquez, V.M., Uebelhoer, L.S., Thapa, M., et al. Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. Hepatology 61 (2015), 843–856.
24. Lightfoot, Y.L., Yang, T., Sahay, B., et al. Colonic immune suppression, barrier dysfunction, and dysbiosis by gastrointestinal bacillus anthracis Infection. PLoS One, 9, 2014, e100532.
25. Segata, N., Izard, J., Waldron, L., et al. Metagenomic biomarker discovery and explanation. Genome Biol, 12, 2011, R60.
26. Ribot, J.C., deBarros, A., Pang, D.J., et al. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol 10 (2009), 427–436.
27. Bonneville, M., O'Brien, R.L., Born, W.K., Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10 (2010), 467–478.
28. Sandler, N.G., Koh, C., Roque, A., et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141 (2011), 1220–1230 1230.e1–e3.
29. Wang, L., Llorente, C., Hartmann, P., et al. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods 421 (2015), 44–53.
30. Kwon, H.S., Yang, E.H., Yeon, S.W., et al. Rapid identification of probiotic Lactobacillus species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. FEMS Microbiol Lett 239 (2004), 267–275.
31. Byun, R., Nadkarni, M.A., Chhour, K.L., et al. Quantitative analysis of diverse Lactobacillus species present in advanced dental caries. J Clin Microbiol 42 (2004), 3128–3136.
32. Wang, X., Sun, R., Wei, H., et al. High-mobility group box 1 (HMGB1)-toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages. Hepatology 57 (2013), 373–384.
33. Hammerich, L., Tacke, F., Role of gamma-delta T cells in liver inflammation and fibrosis. World J Gastrointest Pathophysiol 5 (2014), 107–113.
34. Martins, E.B., Graham, A.K., Chapman, R.W., et al. Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology 23 (1996), 988–993.
35. Maggi, L., Santarlasci, V., Capone, M., et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 40 (2010), 2174–2181.
36. Cani, P.D., Possemiers, S., Van de Wiele, T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58 (2009), 1091–1103.
37. Rahman, K., Desai, C., Iyer, S.S., et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151 (2016), 733–746e12.
38. Zhu, C., Fuchs, C.D., Halilbasic, E., et al. Bile acids in regulation of inflammation and immunity: friend or foe?. Clin Exp Rheumatol 34:Suppl 98 (2016), S25–S31.
39. Heymann, F., Tacke, F., Immunology in the liver—from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13 (2016), 88–110.
40. Sabino, J., Vieira-Silva, S., Machiels, K., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut, 2016, 1–9.
41. Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9 (2009), 799–809.
42. Usami, M., Miyoshi, M., Yamashita, H., Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol 21 (2015), 11597–11608.
43. O'Brien, R.L., Roark, C.L., Born, W.K., IL-17-producing gammadelta T cells. Eur J Immunol 39 (2009), 662–666.
44. Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122 (2005), 107–118.
45. Lohse, A.W., Weiler-Normann, C., Tiegs, G., Immune-mediated liver injury. J Hepatol 52 (2010), 136–144.
46. Tabibian, J.H., O'Hara, S.P., Trussoni, C.E., et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 63 (2016), 185–196.
47. Samuelson, J., Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 43 (1999), 1533–1541.
48. Färkkilä, M., Karvonen, A.-L., Nurmi, H., et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40 (2004), 1379–1386.
49. Gordo-Gilart, R., Andueza, S., Hierro, L., et al. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut 64 (2015), 147–155.